Pyrantel

Summary

Pyrantel (CHEMBL1626223) is an approved small-molecule antinematodal drug (ATC P02CC01); indicated across 1 condition including helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02CC01
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 206.31 Da · C11H14N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1626223
Name	Pyrantel
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	708857
ChEBI	CHEBI:8654
ATC	P02CC01
Molecular formula	C11H14N2S
Molecular weight	206.31
InChIKey	YSAUAVHXTIETRK-AATRIKPKSA-N

SMILES: CN1CCCN=C1/C=C/C2=CC=CS2

IUPAC name: 1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine

ChEBI definition: A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4’-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO ‘Model List of Essential Medicines’.

Pharmacological roles (ChEBI): antinematodal drug.

Also known as: Konvermex, Pirantel, Pyrantel, PYRANTEL, Pyrantel pamoate, pyrantel, Pyrantel (pamoate)

Parent form; salt/anhydrous children: CHEMBL1585303, CHEMBL1599768, CHEMBL2105309

Patent coverage: 1,601 distinct patent families (5,657 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Muscarinic acetylcholine receptor M2, Acetylcholinesterase, Prostaglandin G/H synthase 1, Bile salt export pump.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
helminthiasis	4	MONDO:0004664	EFO:1001342

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03278431	PHASE4	COMPLETED	Triple Combinations Against Hookworm Infections in Lao
NCT02812615	Not specified	UNKNOWN	The Bangladesh Environmental Enteric Dysfunction Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).